Patient characteristics.
| Characteristics | Patients, n = 152 |
|---|---|
| Age, yrs, mean (SD) | 57 (14) |
| Female sex, n (%) | 101 (66) |
| Disease duration, yrs | 3 (2–6) |
| Treatment, n (%) | |
| csDMARD monotherapy | 69 (45) |
| csDMARD combination therapy | 59 (39) |
| bDMARD therapy | 24 (16) |
| Prednisolone | 3 (2) |
| Seropositive (RF and/or ACPA), n (%) | 103/137 (75) |
| Erosive, n (%) | 67 (45) |
| TJC28 | 0 (0–1) |
| SJC28 | 0 (0–2) |
| PtGA, 0–100 mm | 19 (10–36) |
| ESR | 7 (4–13) |
| CRP, mg/l | 5 (1–31) |
| DAS28-ESR, mean (SD) | 2.1 (0.9) |
| DAS28 remission, n (%) | 97/148 (66) |
| VAS pain, 0–100 mm | 15 (3–34) |
| HAQ-DI | 0.25 (0–0.86) |
| EQ-5D | 0.76 (0.69–1.00) |
| SF-36 PCS, mean (SD) | 46 (11) |
| SF-36 MCS, mean (SD) | 51 (10) |
| FACIT-F | 42 (34–47) |
| MBDA score, 1–100 | 31 (18–39) |
| Calprotectin, ng/ml | 2358 (1487–3358) |
| CXCL10, pg/ml | 198 (143–291) |
| No. (%) patients with GSUS > 0 | 104/104 (100) |
| Total GSUS score, /36 | 12 (8–14) |
| No. (%) patients with PDUS > 0 | 93 (90) |
| Total PDUS score, /36 | 2 (1–4) |
Data are median (IQR) unless otherwise specified. IQR: interquartile range; csDMARD: conventional synthetic disease-modifying antirheumatic drug; bDMARD: biologic DMARD; RF: rheumatoid factor; ACPA: anticitrullinated protein antibody; TJC28: tender joint count at 28 joints; SJC28: swollen joint count at 28 joints; PtGA: patient’s global assessment; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; DAS28: 28-joint count Disease Activity Score; VAS: visual analog scale; HAQ-DI: Health Assessment Questionnaire–Disability Index; SF-36 PCS: Medical Outcomes Study Short Form-36 physical component summary; SF-36 MCS: Medical Outcomes Study Short Form-36 mental component summary; FACIT-F: Functional Assessment of Chronic Illness Therapy Fatigue scale; MBDA: multibiomarker disease activity; GSUS: greyscale ultrasound synovial hypertrophy; PDUS: intraarticular power Doppler ultrasound signals.